Solvay


Caught on the wrong foot

24/06/20 -"Solvay’s €1.5bn impairment of the back of the current challenging business situation is the price the current management has to pay for the predecessor’s expensive decisions. The ..."

Pages
64
Language
English
Published on
24/06/20
You may also be interested by these reports :
06/08/26
SGL Carbon delivered a resilient first-half performance despite a difficult industrial environment. Sales declined 13% YoY due to the restructuring ...

06/08/26
The decline in the target price is due to changes made to the peer group for Umicore, apart from updates to earnings estimates (discussed below). We ...

03/08/26
Umicore posted strong results for H1 2026, driven by market share gains in Catalysis and a metals rally in Q1. However, we see a repeat of H1 in the ...

31/07/26
Fuchs reported strong Q2 numbers, supported by positive pricing and market share gains – likely temporary. Growth in sales and earnings was recorded ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO